Related Experiment Video
Updated: Jun 3, 2026
11:32
Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria
Published on: February 23, 2014
[Pneumococci isolated from vaccinated children with pneumonia]
D Gendrel1, T Lecarpentier1, C Menager1
1Service de pédiatrie, hôpital Necker, université Paris Descartes, 149, rue de Sèvres, 75015 Paris, France.
Summary
The 7-valent pneumococcal conjugate vaccine did not prevent all pneumococcal pneumonia in children. Non-vaccine serotypes caused infections, indicating the need for broader protection against community-acquired pneumonia.
Area of Science:
- Pediatric infectious diseases
- Vaccinology
- Microbiology
Context:
- Community-acquired pneumonia (CAP) is a significant cause of childhood hospitalization.
- The 7-valent pneumococcal conjugate vaccine (PCV7) was introduced to prevent pneumococcal infections.
- This study investigated pneumococcal pneumonia in children vaccinated with PCV7.
Purpose:
- To assess the effectiveness of PCV7 against pneumococcal pneumonia in hospitalized children.
- To identify the serotypes causing pneumococcal pneumonia post-PCV7 vaccination.
- To evaluate the continued need for bacteriologic surveillance of CAP.
Summary:
- Ten of 76 children hospitalized for pneumonia (2006-2009) had confirmed pneumococcal infections despite PCV7 vaccination.
- All identified pneumococci belonged to non-vaccine serotypes (1, 5, 7F, 19A).
- The incidence of pneumococcal pneumonia remained similar to pre-vaccine eras, suggesting PCV7 limitations.
Impact:
- Findings support the potential utility of the 13-valent pneumococcal conjugate vaccine (PCV13) for broader CAP prevention.
- Highlights the ongoing necessity of bacteriologic surveys to monitor evolving pneumococcal epidemiology.
- Informs public health strategies for optimizing pneumonia prevention in children.
More Related Videos
Related Concept Videos
01:29Pneumonia I: Introduction
Pneumonia is an infection of the lower respiratory tract that leads to inflammation of the lung parenchyma, often resulting in the accumulation of inflammatory exudate in the alveoli and airways. Unlike the watery, low-protein fluid exudate in pulmonary edema, the exudate in this case is a thick fluid rich in immune cells, proteins, and debris produced during infection and inflammation.This impairs gas exchange and can lead to consolidation of lung tissue. The infection may be caused by a...
01:30Pneumonia I: Introduction
Pneumonia is an acute respiratory infection that targets the lungs, specifically the alveoli. These tiny air sacs, essential for oxygen exchange, become engorged with pus and fluid, severely hindering breathing, decreasing oxygen absorption, and causing significant pain and discomfort during respiration.
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
01:29Pneumonia II: Pathophysiology
The pathophysiology of pneumonia involves the following steps:
01:30Pneumonia III: Complications and Assessment
Pneumonia poses the potential for numerous complications that warrant consideration. These complications include the following:
01:14Atypical Pneumonia
Atypical pneumonia, often caused by Mycoplasma pneumoniae, is a form of pulmonary infection that differs from the classical presentation of bacterial pneumonia in both its cause and clinical symptoms. Mycoplasma pneumoniae is a pleomorphic bacterium notable for its lack of a rigid cell wall. This structural characteristic imparts resistance to beta-lactam antibiotics and significantly influences the bacterium’s behavior within the human host.Other pathogens responsible for the disease include...
01:28Pneumonia IV: Management
The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include: